Mentioned On
Episode Mentions
The Top Line · Jul 10, 2026
A $10B deal, China trial scrutiny and highlights from ADA 2026
“Acquired by Vertex for $10B; brings approved endocrine drug Pelsonify and investigational CAH/Cushing syndrome treatment”
Vertex Crinetics acquisition and rare endocrine disease expansionClinical trial regulation and China data integrity scrutinyGLP-1 agonist efficacy and weight loss outcomes
View Analysis